Researcher:
Esen, Barış

Profile Picture
ORCID

Job Title

Teaching Faculty

First Name

Barış

Last Name

Esen

Name

Name Variants

Esen, Barış

Email Address

Birth Date

Filters

20233

Advanced Search

Filter by

Settings

Researcher Of Publications: search.filters.isAuthorOfPublication.eaf2f24f-40b8-452e-91bf-eb1142f5e0df

Search Results

Now showing 1 - 3 of 3
  • Placeholder
    PublicationMetadata only
    Postchemotherapy robotic retroperitoneal lymph node dissection for non-seminomatous germ cell tumors in the lateral decubitus position: oncological and functional outcomes
    (Springer, 2023) Kilic, Mert; N/A; Kordan, Yakup; Köseoğlu, Ersin; Esen, Barış; Özkan, Arif; Kiremit, Murat Can; Esen, Tarık; Faculty Member; Faculty Member; Teaching Faculty; Doctor; Faculty Member; Faculty Member; School of Medicine; School of Medicine; School of Medicine; N/A; School of Medicine; School of Medicine; N/A; N/A; N/A; Koç University Hospital; N/A; N/A; 157552; 350876; 199167; 222920; 50536
    Purpose Retroperitoneal lymph node dissection (RPLND) is recommended for residual masses following chemotherapy for non-seminomatous germ cell tumors (NSGCT). Recently, aberrant recurrence patterns were reported in patients who underwent robotic RPLND. We aimed to evaluate perioperative safety in addition to functional and early oncological outcomes of postchemotherapy robotic RPLND (pcR-RPLND) for NSGCT.Methods A total of 25 patients with NSGCT who underwent a pcR-RPLND between January 2011 and June 2022 were evaluated retrospectively. Descriptive statistics were provided for demographics, clinical characteristics, intraoperative and postoperative parameters. Functional and oncological outcomes were recorded.Results The median patient age was 28.9 years (IQR 21.5-32.4). The median retroperitoneal tumor size was 2.6 cm (IQR 1.5-3.5). Intraoperative complications occurred in only one case and the open conversion rate was 12%. There were seven cases with postoperative complications (Clavien grade II: 5 and IIIa: 2). Patients were followed for a median of 33.2 months (IQR 14.8-43.0). Antegrade ejaculation was preserved in 85.7% of the patients. Two patients (8%) relapsed and both had out-of-field recurrences at unusual sites (perinephric fat and omentum). of those, one patient died (4%) of testicular cancer.Conclusion pcR-RPLND is a feasible and technically reproducible procedure with favorable perioperative morbidity, low rate of complications, and acceptable postoperative ejaculatory function. Although the recurrence rate was low (8%), recurrences were observed at unusual sites. Further studies are required to investigate any association between the robotic approach and aberrant recurrence patterns.
  • Placeholder
    PublicationMetadata only
    [Ga-68]Ga-PSMA-11 and [F-18]FDG uptake of venous tumor thrombus in inferior vena cava and left common iliac vein from prostate cancer on positron emission tomography
    (Springer, 2023) Kabaoğlu, Zeynep Ünal; N/A; Seymen, Hülya; Esen, Barış; Kulaç, İbrahim; Aksoy, Murat; Demirkol, Mehmet Onur; Kordan, Yakup; Teaching Faculty; Teaching Faculty; Faculty Member; Other; Faculty Member; Faculty Member; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; 350778; 199167; 170305; N/A; 196946; 157552
    N/A
  • Placeholder
    PublicationMetadata only
    Prostate-specific membrane antigen positron emission tomography as a biomarker to assess treatment response in patients with advanced prostate cancer
    (Elsevier, 2023) Herrmann, Ken; Bavbek, Sevil; Esen, Tarık; Kordan, Yakup; Esen, Barış; Tilki, Derya; Faculty Member; Faculty Member; Teaching Faculty; Other; School of Medicine; School of Medicine; School of Medicine; School of Medicine; 50536; 157552; 199167; N/A
    Context: Prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) has superior accuracy for detection of metastatic lesions in patients with prostate cancer (PC). Although PSMA PET has a prominent role in primary and secondary imaging of PC, data on its role in assessing treatment response in advanced PC are limited. Objective: To review current data in the literature regarding the impact of antiandrogen therapy on PSMA expression of metastatic sites and the role of serial (baseline and at least 1 follow-up scan) PSMA PET to assess treatment response in patients with metastatic PC. Evidence acquisition: A comprehensive literature search in the PubMed database was performed using the terms “PSMA expression prostate”, “PSMA regulation”, “PSMA PET response assessment”, and “serial PSMA PET”. Evidence synthesis: Serial PSMA PET studies (baseline and at least 1 follow-up scan) provide valuable data regarding PSMA expression changes after systemic treatment in patients with metastatic PC. PSMA PET–detected flare and upregulation of PSMA expression following hormonal intervention seem to be early events resolving after 3 mo of treatment. PSMA PET imaging is essential in selecting patients for 177Lu-PSMA radioligand therapy (RLT). Growing evidence favors its use in assessing treatment responses after RLT. Preliminary evidence indicates the value of PSMA PET for assessment of the treatment response in patients receiving systemic treatment other than RLT for metastatic PC. Conclusions: PSMA flare following antiandrogen therapy seems to be an early event and thus PET scans should be performed no earlier than 3 mo after the start of treatment. PSMA PET has a promising role in tailoring treatment according to the specific needs of individual patients and assessing responses following systemic treatment in patients with advanced PC. Patient summary: This review describes how a sensitive imaging method can be used to assess the tumor response to treatment for metastatic prostate cancer.